Moreover, our study of molecular biomarkers, including the Bif-1 gene, could pave the way for biomarkers with therapeutic value shortly; second, it could lead to the production of effective drugs for the treatment of breast cancer patients and especially those patients with Triple Negative Breast Cancer. This evidence concerns the gene SH3GLB1 and breast carcinoma.